Yes, cannabinoids can ease one symptom of multiple sclerosis: muscle stiffness and spasms (spasticity), as reported by patients, is the best-supported use of cannabis medicine in neurology. A 2022 Cochrane review found that nabiximols, a THC and CBD mouth spray, probably reduces spasticity in the short term. Evidence for MS pain, bladder problems and sleep is weaker, cannabis does not slow the disease, and no cannabis product is FDA-approved for MS.
Multiple sclerosis is an autoimmune disease that damages the protective coating of nerves in the brain and spinal cord. Many people with MS live with stiffness, painful spasms, nerve pain and poor sleep, and surveys have long shown that a sizable share try cannabis for relief. This is one area where the research is relatively solid. This guide explains what works, what does not, and the trade-offs, as of October 2026.
Cannabis and MS: Evidence at a Glance
| Claim | Evidence level | Source |
|---|---|---|
| Oral cannabinoids improve patient-reported spasticity | Substantial | National Academies 2017 |
| Nabiximols reduces spasticity in the short term | Moderate certainty (5 trials, 1,143 people) | Cochrane 2022 |
| Cannabinoids improve spasticity measured by a clinician | Limited | National Academies 2017 |
| Cannabinoids reduce MS nerve pain | Uncertain (very low certainty) | Cochrane 2022 |
| Cannabinoids improve short-term sleep in MS | Moderate | National Academies 2017 |
| Cannabinoids improve quality of life | Little to no effect (low certainty) | Cochrane 2022 |
| Cannabis slows MS progression | No evidence | None of the reviews above |
Spasticity: The Strongest Evidence
Spasticity is stiffness and involuntary muscle tightening, often in the legs, that can make walking hard and disturb sleep. The National Academies’ 2017 report placed “patient-reported multiple sclerosis spasticity symptoms” among the few uses with substantial evidence for oral cannabinoids.
The most complete review is the 2022 Cochrane review of 25 randomized trials with 3,763 participants. Its key findings:
- Nabiximols roughly doubled to tripled the odds that a patient reported an important reduction in spasticity. In absolute terms, about 216 more people per 1,000 reported benefit than with placebo.
- Cannabinoids increased the number of people who said their overall health was much or very much improved, by about 113 per 1,000.
- Quality of life scores barely changed.
- Most trials lasted 3 to 48 weeks, so long-term effects are less certain.
There is a catch. Improvements show up more clearly when patients rate their own stiffness than when doctors measure muscle tone with standard scales. That gap is why the National Academies rated clinician-measured spasticity evidence as only limited. Patients may be detecting real changes the scales miss, or the difference may partly reflect expectations, since THC’s effects are hard to hide in a blinded trial.
What Is Nabiximols (Sativex)?
Nabiximols, sold as Sativex, is a mouth spray made from cannabis plant extracts. Each spray delivers 2.7 mg of THC and 2.5 mg of CBD. It is approved for MS spasticity in the UK, Canada and a number of European countries, usually for patients who have not responded to standard drugs such as baclofen or tizanidine. It is not FDA-approved in the US. American patients who want a pharmaceutical option can ask about dronabinol or nabilone, which are FDA-approved for other conditions and would be used off-label.
Pain, Bladder and Sleep
Nerve pain
MS often causes burning, tingling or electric-shock pain. A 2005 trial of 66 patients found that the THC/CBD spray reduced central pain and sleep disturbance over four weeks compared with placebo (Rog et al., Neurology). But when Cochrane pooled all trials in 2022, it rated the evidence on chronic nerve pain as very low certainty and said it is uncertain whether cannabinoids reduce MS pain intensity.
Bladder problems
The National Center for Complementary and Integrative Health reports small improvements in bladder problems in some studies, but older neurology guidelines rated nabiximols probably ineffective for bladder incontinence.
Sleep
The National Academies found moderate evidence that cannabinoids, mainly nabiximols, improve short-term sleep in people with MS. It is not clear whether this is a direct effect or a result of less pain and stiffness.
Does Cannabis Slow MS?
No. Cannabis treats symptoms only. It does not reduce relapses, brain lesions or disability progression in any trial. Disease-modifying therapies are the only treatments shown to change the course of MS, and cannabis should never replace them.
Risks and Side Effects
The 2022 Cochrane review found that cannabinoids probably cause somewhat more people to stop treatment because of side effects, and increase nervous system and psychiatric side effects compared with placebo. Specific concerns for people with MS:
- Dizziness, drowsiness and dry mouth: the most common effects reported in the trials.
- Balance and falls: MS often affects balance already, and THC can worsen it.
- Thinking and memory: MS can cause cognitive problems, and THC impairs attention and memory while active.
- Mood: depression is common in MS. The National Academies found limited evidence that cannabinoids do not improve depressive symptoms in MS; see our cannabis and depression article.
- Smoking: smoking anything harms the lungs. Sprays, capsules and oils avoid that.
- Dependence: regular THC use can lead to cannabis use disorder.
- Drug interactions: cannabinoids add to the sedation of muscle relaxants, gabapentin and other common MS medicines.
Talk to Your Doctor
If spasticity or pain is not well controlled, ask your neurologist about all options, including physical therapy, baclofen, tizanidine, gabapentin and botulinum toxin. If you want to try cannabis, ask what formulation and ratio makes sense, how to start low and increase slowly, and how it interacts with your current medicines. Track stiffness, pain and sleep for a few weeks before and after. Many patients in trials used far fewer sprays than the maximum allowed, so a little often goes a long way.
Legal Status and Buying
MS is a qualifying condition in most state medical cannabis programs. In adult-use states such as Washington and Oregon, adults 21 and older can buy from licensed stores; our Washington dispensary directory lists licensed stores. Dispensary products are not the same as nabiximols, so ask a pharmacist or knowledgeable budtender about THC and CBD content per dose. Federal law still treats marijuana as illegal; see our federal law guide.
Cannabis and Multiple Sclerosis FAQ
Does cannabis help MS spasticity?
Yes, for many patients by their own report. Systematic reviews rate the evidence as moderate to substantial for short-term, patient-reported improvement, especially with nabiximols.
Is Sativex available in the US?
No. Sativex (nabiximols) is approved in the UK, Canada and several European countries but not by the FDA.
Is CBD alone good for MS?
Most MS trials tested THC or THC combined with CBD. There is little good evidence on CBD by itself for MS symptoms.
Can cannabis cure or slow MS?
No. It may ease some symptoms but does not affect relapses or disease progression. Keep taking your disease-modifying therapy.
Does cannabis help MS pain?
Some individual trials found benefit for nerve pain, but pooled evidence is very uncertain. It may help some people, and others feel no difference.
What are the side effects of cannabis for MS?
Dizziness, drowsiness, dry mouth and trouble concentrating are the most common. Cannabinoids can also worsen balance and mood in some people.
Related reading: cannabis and epilepsy and our full cannabis research section.
For adults 21+ in legal states. General information, not medical advice. Talk to a doctor before using cannabis for a health condition.